Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.
Acta Ophthalmol. 2014 Dec;92(8):713-23. doi: 10.1111/aos.12463. Epub 2014 Jun 12.
Broadhead GK 1 , Hong T, Chang AA.
Anti-vascular endothelial growth factor (anti-VEGF) agents represent the current standard of care for neovascular age-related macular degeneration (nAMD). Although effective in a majority of cases, a significant proportion of patients have persisting retinal exudation despite regular anti-VEGF therapy. This exudation is considered to produce poorer visual outcomes in these patients. Some of these patients may have misdiagnosed nAMD variants such as polypoidal choroidal vasculopathy; however, the majority of these eyes have what has been termed treatment-resistant nAMD. Currently, the best way to care for these patients is uncertain. Here, we review the evidence for different approaches to the management of treatment-resistant nAMD, including high-dose anti-VEGF therapy, combination regimes and switching of anti-VEGF agents, and discuss possible therapeutic approaches for patients with treatment-resistant nAMD.
Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.Read more
Acta Ophthalmol. 2014 Dec;92(8):713-23. doi: 10.1111/aos.12463. Epub 2014 Jun 12. Broadhead GK 1 , Hong T, Chang AA.
Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.Read more
Graefes Arch Clin Exp Ophthalmol. 2015 Aug;253(8):1217-25. doi: 10.1007/s00417-014-2799-8. Epub 2014 Sep 10. Zhu M 1 , Chew
Dietary modification and supplementation for the treatment of age-related macular degeneration.Read more
Nutr Rev. 2015 Jul;73(7):448-62. doi: 10.1093/nutrit/nuv005. Epub 2015 Apr 28. Broadhead GK 1 , Grigg JR 2 ,